| Ms Tameika M Mclean, OTR/L | |
|
2745 29th St Nw, Apt 619, Washington, DC 20008-5531 | |
| (917) 599-7221 | |
| Not Available |
| Full Name | Ms Tameika M Mclean |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist |
| Location | 2745 29th St Nw, Washington, District Of Columbia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043698277 | NPI | - | NPPES |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Tameika M Mclean, OTR/L 2745 29th St Nw, Apt 619, Washington, DC 20008-5531 Ph: (917) 599-7221 | Ms Tameika M Mclean, OTR/L 2745 29th St Nw, Apt 619, Washington, DC 20008-5531 Ph: (917) 599-7221 |
News Archive
Minimally-invasive surgery to remove blood from the brain along with intermittent dosing of a clot-busting drug after a brain bleed may not improve function better than medical therapy but it was associated with fewer deaths, according to late-breaking science presented at the American Stroke Association's International Stroke Conference 2019, a world premier meeting for researchers and clinicians dedicated to the science and treatment of cerebrovascular disease.
Research in the past several years has shown that children can outgrow a diagnosis of autism spectrum disorder, once considered a lifelong condition.
Cerenis Therapeutics SA (Cerenis), a biopharmaceutical company developing novel high-density lipoprotein (HDL) therapies to treat cardiovascular and other metabolic diseases, and Groupe Novasep (Novasep), a leading supplier of manufacturing solutions to the life sciences industries, announce today that they have received French Government funding through OSEO to finance the development of CER-001, a Cerenis HDL mimetic.
Breast cancer, in the stage with distant metastases, is an incurable disease with a 5 years survival rate of about 5-10%. Immunotherapy has recently improved survival in metastatic breast cancer patients with breast cancer harboring the expression of HER 2 receptor.
A Mayo Clinic study involving 5,540 patients with metastatic colorectal cancer finds that maintenance chemotherapy after initial treatment is more beneficial for patients whose disease is under control, compared with more aggressive treatment.
› Verified 2 days ago
Miss Samora Casimir, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 6900 Georgia Ave Nw, Washington, DC 20307 Phone: 443-802-7824 | |
Petra Doyle, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 201 8th St Ne, Suite 301, Washington, DC 20002 Phone: 202-544-5439 | |
Lisa George, MS OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 4400 Jenifer St Nw, Suite 280, Washington, DC 20015 Phone: 202-244-8089 | |
Andrea L. Meehan, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 50 Irving St Nw, Washington, DC 20422 Phone: 202-745-8000 | |
Samantha Fulp, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 101 T St Ne, Washington, DC 20002 Phone: 956-278-0770 | |
Tsegie Kassahun, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1818 Newton St Nw, Washington, DC 20010 Phone: 202-328-7400 | |
Dr. Nikia Brocks, OTD,OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 2411 32nd St Se, Washington, DC 20020 Phone: 202-575-5404 Fax: 301-576-5404 |